Theriva Biologics, Inc.
TOVXNYSEHealthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$24.1M | −$26.3M | −$21.4M | −$21.6M | −$14.3M | −$10.2M |
| Net income | −$23.7M | −$25.7M | −$18.3M | −$19.7M | −$14.3M | −$10.0M |
| Total assets | $38.2M | $35.4M | $55.2M | $71.9M | $70.4M | $8.4M |
| Total liabilities | $22.9M | $16.3M | $15.5M | $17.3M | $5.0M | $3.2M |
| Equity | $15.4M | $19.1M | $37.0M | $62.2M | $65.4M | −$4.8M |
| EPS (diluted) | $-2.08 | $-19.03 | $-28.48 | $-1.31 | $-1.90 | $-0.66 |
| Shares out. | 2.8M | 17.1M | 15.1M | 158.4M | 129.7M | 17.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −154.3%
- Return on assets
- −62.1%
- Return on capital (ROCE)
- −85.2%
- Liabilities / assets
- 59.8%
- Debt / equity
- 1.49×
- Book value / share
- $5.53
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -32.82distress
- Accruals / assets
- −18.5%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 1 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 2, 2013
- NT 10-Kmissed a reporting deadline ↗Mar 28, 2003
- NT 10-Kmissed a reporting deadline ↗Mar 30, 1998
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Jeffrey Matthew Gryga Irrevocable TrustPassive (13G)Nov 10, 2025
- Empery Asset Management, LpPassive (13G)Oct 21, 2025
- Cvi Investments, Inc.Passive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.1M | 1.3 | -52.3% |
| Apr 30, 2026 | 8.5M | 1.0 | +234.4% |
| Apr 15, 2026 | 2.5M | 1.0 | -62.9% |
| Mar 31, 2026 | 6.9M | 1.0 | +25.3% |
| Mar 13, 2026 | 5.5M | 3.5 | -10.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Regulation FD disclosure · Other material eventApr 17, 2026
- Other material eventApr 9, 2026
- Regulation FD disclosure · Other material eventMar 23, 2026
- Results of operationsMar 12, 2026
- Entered a material agreement · Regulation FD disclosureFeb 18, 2026
- Other material eventFeb 12, 2026
- Other material eventJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 5, 2026
- 8-KFORM 8-KMay 5, 2026
- DEF 14AApr 30, 2026
- PRE 14AApr 20, 2026
- 8-KFORM 8-KApr 17, 2026
- 8-KFORM 8-KApr 9, 2026
- 8-KFORM 8-KMar 23, 2026
- DEF 14AMar 16, 2026
- 10-KMar 12, 2026
- 8-KFORM 8-KMar 12, 2026
- PRE 14AMar 4, 2026
- 8-KFORM 8-KFeb 18, 2026
- 8-KFORM 8-KFeb 12, 2026
- 8-KFORM 8-KJan 12, 2026
- 4OWNERSHIP DOCUMENTJan 6, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.